Liraglutide: the complete guide

How Liraglutide works

Liraglutide binds and activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite via central satiety pathways.

Typical Liraglutide dosage

Commonly reported research ranges: Titration: 0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg daily (Saxenda); 0.6 mg → 1.8 mg daily (Victoza).

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute Liraglutide

A widely used reconstitution for a 3 mg vial is 0.5 ml of bacteriostatic water. With a typical 600 mcg dose this works out to the unit count shown in the calculator below.

Open the Liraglutide reconstitution calculator →

Half-life and administration frequency

Approximately 13 hours (once-daily dosing).

This half-life informs how often Liraglutide is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

• Nausea (especially during titration)
• Vomiting
• Diarrhea or constipation
• Injection-site reactions
• Rare: pancreatitis, gallbladder events

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common Liraglutide stacks

• Typically used as monotherapy with a GLP-1 regimen

Storage and handling

Refrigerated 2–8 °C before first use. In-use pen at room temperature (below 30 °C) for up to 30 days.

FDA and regulatory status

FDA approved. Victoza for type 2 diabetes; Saxenda for chronic weight management.

Liraglutide clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

For Liraglutide, the public evidence base is summarized in the references section; not every research peptide has robust registered human clinical trials.

Frequently asked questions

References

1. Victoza (liraglutide) — FDA Drugs@FDA — U.S. Food and Drug Administration. FDA approval label for type 2 diabetes indication
2. Saxenda (liraglutide 3 mg) — FDA Drugs@FDA — U.S. Food and Drug Administration. FDA approval label for chronic weight management
3. LEADER cardiovascular outcomes trial — PubMed. Landmark CV outcomes trial establishing liraglutide cardiovascular benefit

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.